文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

重复全脑放疗时的预后评估:再照射评分

Estimating prognosis at the time of repeat whole brain radiation therapy for multiple brain metastases: The reirradiation score.
PubMed 文献 · Adv Radiat Oncol · 2017-06-14

该多中心汇总分析纳入205例接受两次全脑放疗的多发脑转移患者,评估第二次WBRT前RPA分级的预后价值。RPA分级与中位生存显著相关,但多因素分析显示KPS<80、颅外转移、间隔<9个月、小细胞肺癌组织学及原发灶未控与更短生存相关,据此构建的ReRT评分可区分生存。

要点

  • 第二次WBRT前RPA分级与中位生存相关,但多因素分析未显示其独立预后价值。
  • ReRT评分基于KPS<80、颅外转移、间隔<9个月、小细胞肺癌、原发灶未控五项因素。
  • ReRT评分分组对应的中位生存范围为2.2至7.2个月,组间差异显著。

核心结论

  • 在 largest reported 接受重复全脑放疗的队列中,RPA评分未能预测中位生存,而新构建的ReRT评分可区分不同生存组。

研究设计与样本

  • 多中心汇总分析纳入205例来自任何实体原发肿瘤、有2个或以上脑转移且接受2程WBRT的患者。

主要发现

  • 单因素和多因素分析显示KPS<80、颅外转移、两次WBRT间隔<9个月、小细胞肺癌组织学及原发灶未控与更短中位生存显著相关。
  • 对上述每项因素赋1分构建ReRT评分,基于评分分组的中位生存范围为2.2至7.2个月,组间中位生存差异显著。

临床怎么用

  • ReRT评分基于 readily available 临床信息,可用于重复WBRT前评估预后并辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Whole brain radiation therapy (WBRT) remains the standard of care for patients with multiple brain metastases, but more than half of treated patients will develop intracranial progression. Because there is no clear consensus on the optimal therapeutic approach, a prognostic index would be helpful to guide treatment options at progression. We explored whether the recursive partitioning analysis (RPA) score prior to repeat WBRT is predictive of survival. METHODS AND MATERIALS: This multi-institutional pooled analysis included patients with 2 or more brain metastases from any solid primary tumor that was treated with 2 courses of WBRT. Information on demographics, disease characteristics, and intervals between courses was collected. RPA class was abstracted or retrospectively assigned, and descriptive statistics calculated. Median survival (MS) was determined using the Kaplan-Meier method and compared using log rank tests. Univariate and multivariate analyses were performed via Cox regression analysis. RESULTS: For 205 patients, the median age was 55 years (range, 25-83 years), 68% were female, 40.5% had non-small cell lung cancer, and 31.2% had small cell lung cancer. Prior to the second WBRT, 4.9% of patients were RPA class 1, 36.6% were RPA2, and 58.5% were RPA3, with an MS of 7.5 months (95% confidence interval [CI], 4.7-10.3), 5.2 months (95% CI, 3.7-6.7 months), and 2.9 months (95% CI, 2.2-2.9 months), respectively (P = .001). On univariate and multivariate analyses, a Karnofsky Performance Status of <80, extracranial metastases, interval between courses <9 months, small cell lung cancer histology, and uncontrolled primary significantly correlated with shorter MS. By assigning a score of 1 to each of these factors, a new prognostic index was created, the reirradiation (ReRT) score. Survival on the basis of ReRT score grouping ranged from 2.2 to 7.2 months and demonstrated significant differences in MS. CONCLUSIONS: In the largest reported cohort to receive repeat WBRT, application of the RPA score was not predictive of MS. The new ReRT score is a simple tool based on readily available clinical information.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Logie N, Jimenez RB, Pulenzas N, et al. Estimating prognosis at the time of repeat whole brain radiation therapy for multiple brain metastases: The reirradiation score. Adv Radiat Oncol. 2017. PMID: 29114606. doi:10.1016/j.adro.2017.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。